Co-Authors
This is a "connection" page, showing publications co-authored by Mark Tenforde and Natasha Halasa.
Connection Strength
0.827
-
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
Score: 0.241
-
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. Clin Infect Dis. 2021 Aug 06.
Score: 0.240
-
Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19-Nashville, Tennessee. Clin Infect Dis. 2021 05 04; 72(9):1645-1648.
Score: 0.059
-
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021 05 01; 78(5):536-547.
Score: 0.059
-
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 03 16; 325(11):1074-1087.
Score: 0.058
-
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 27; 69(47):1762-1766.
Score: 0.057
-
Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers, April-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 04; 69(35):1221-1226.
Score: 0.056
-
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 07 23; 383(4):334-346.
Score: 0.056